Citations

Clear

371 citation(s) found for "Cho, B".

Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019
Kocarnik, Jonathan , Compton, Kelly, Dean, Frances , Fu, Weijia , Gaw, Brian, Harvey, James , Henrikson, Hannah , Lu, Dan , Pennini, Alyssa, Xu, Rixing, Ababneh, Emad , Abbasi‐Kangevari, Mohsen , Abbastabar, Hedayat , Abd‐Elsalam, Sherief , Abedi, Aidin , Abidi, Hassan , Abolhassani, Hassan , Adedeji, Isaac Akinkunmi , Advani, Shailesh M, Aghaali, Mohammad , Ahmad, Tauseef , Rashid, Tarik A. , Salih, Yusra Ahmed , Aklilu, Addis , Akram, Tayyaba , Akunna, Chisom Joyqueenet , Hamad, Hanadi Al , Alahdab, Fares , Alimohamadi, Yousef, Alipour, Vahid, Alkhayyat, Motasem , Almasri, Nihad A. , Al‐Maweri, Sadeq Ali , Almustanyir, Sami , Alonso, Nivaldo , Alvis‐Guzmán, Nelson , Amu, Hubert , Ansari, Fereshteh, Antwi, Maxwell Hubert , Anvari, Davood , Anyasodor, Anayochukwu Edward , Aqeel, Muhammad , Arabloo, Jalal , Aremu, Olatunde , Ariffin, Hany , Aripov, Timur , Arshad, Muhammad , Artaman, Al, Arulappan, Judie , Jafarabadi, Mohammad Asghari , Ashraf, Tahira , Atorkey, Prince , Ausloos, Marcel , Awedew, Atalel Fentahun , Quintanilla, Beatriz Paulina Ayala , Ayenew, Temesgen , Azab, Mohammed A. , Azadnajafabad, Sina , Jafari, Amirhossein Azari , Azarian, Ghasem , Badiye, Ashish , Bahadory, Saeed , Baig, Atif Amin , Baker, Jennifer L. , Balakrishnan, Senthilkumar , Bärnighausen, Till , Barone‐Adesi, Francesco , Barrow, Amadou , Belgaumi, Uzma , Bezabhe, Woldesellassie, Bezabih, Yihienew Mequanint , Bhagat, Devidas S. , Bhagavathula, Akshaya Srikanth , Bhardwaj, Nikha , Bhaskar, Sonu , Bhojaraja, Vijayalakshmi S, Bibi, Sadia , Bijani, Ali , Bisignano, Catherine, Bolarinwa, Obasanjo Afolabi , Bolla, Srinivasa Rao , Braithwaite, Dejana , Brar, Amanpreet , Brenner, Hermann , Bustamante-Teixeira, Maria Teresa , Butt, Nadeem Shafique , Butt, Zahid A , Santos, Florentino Luciano Caetano dos , Cao, Yin , Carreras, Giulia , Catalá-López, Ferrán , Cembranel, Francieli , Cerin, Ester , Cernigliaro, Achille , Chakinala, Raja Chandra , Chattu, Soosanna Kumary , Chattu, Vijay Kumar , Chaturvedi, Pankaj, Chimed‐Ochir, Odgerel , Cho, Daniel , Chu, Dinh‐Toi , Conde, João , Cortés, Sandra , Cortesi, Paolo Angelo, Costa, Vera Marisa , Cunha, Amanda Ramos da , Dadras, Omid , Dagnew, Amare Belachew , Dandona, Lalit , Dandona, Rakhi , Hoz, Fernando de la , Dhamnetiya, Deepak , Dhimal, Mandira Lamichhane , Díaz, Daniel , Djalalinia, Shirin , Doaei, Saeid , Dorostkar, Fariba, Driscoll, Tim , Ebrahimi, Hedyeh , Eftekharzadeh, Sahar , Tantawi, Maha El , El‐Abid, Hassan , Elbarazi, Iffat , Elhabashy, Hala Rashad , Elhadi, Muhammed , Eshrati, Babak, Esmaeilzadeh, Firooz , Etemadi, Arash , Ezzikouri, Sayeh , Faisaluddin, Mohammed, Fares, Jawad , Farzadfar, Farshad , Feroze, Abdullah , Desideri, Lorenzo Ferro , Fischer, Florian , Fisher, James L. , Fukumoto, Takeshi , Gad, Mohamed M. , Fonseca, Mariana Gaspar, Obsa, Abera Getachew, Ghafourifard, Mansour , Ghashghaee, Ahmad , Ghith, Nermin , Gholamalizadeh, Maryam , Gilani, Syed Amir , Gizaw, Abraham Tamirat , Glasbey, James , Golechha, Mahaveer , Goleij, Pouya , Gopalani, Sameer Vali , Gorini, Giuseppe , Goudarzi, Houman , Gubari, Mohammed Ibrahim Mohialdeen , Guerra, Maximiliano Ribeiro, Guha, Avirup , Gunasekera, Sanjeeva , Gupta, Bhawna , Gupta, Vivek , Gutiérrez, Reyna Alma, Hafezi‐Nejad, Nima , Haider, Mohammad Rifat , Hameed, Sajid , Hanif, Asif , Haque, Shafiul , Harlianto, Netanja I. , Hasaballah, Ahmed I , Hay, Simon I , Heidari, Golnaz , Herrera-Serna, Brenda Yuliana , Herţeliu, Claudiu , Hezam, Kamal , Hossain, Mohammad Bellal , Hosseini, Mohammad‐Salar , Hosseini, Mostafa, Hosseinzadeh, Mehdi , Hostiuc, Mihaela , Househ, Mowafa , Hsaïri, Mohamed, Huang, Junjie , Hugo, Fernando Neves , Hussain, Rabia , Hussein, Nawfal R , Hwang, Bing‐Fang , Ibitoye, Segun Emmanuel , Ida, Fidelia , Ikuta, Kevin S , Ilić, Irena , Irham, Lalu Muhammad , Islam, Jessica Y. , Islam, Sheikh Mohammed Shariful , Ismail, Nahlah Elkudssiah , Isola, Gaetano , Iwagami, Masao , Jacob, Louis , Jain, Vardhmaan , Jakovljević, Mihajlo, Javaheri, Tahereh , Jayaram, Shubha, Jha, Ravi Prakash , Jonas, Jost B, Joó, Tamás , Joseph, Nitin , Joukar, Farahnaz, Jürisson, Mikk , Kalankesh, Leila R , Kalhor, Rohollah , Kalkonde, Yogeshwar , Kamath, Ashwin , Al-Salihi, Nawzad Kameran, Kandel, Himal , Kapoor, Neeti , Kasa, Ayele Semachew , Keshavarz, Pedram , Keykhaei, Mohammad , Khader, Yousef , Khalilov, Rovshan , Khan, Maseer , Khan, Md Nuruzzaman , Khan, Moien AB , Khang, Young-Ho, Khater, Amir M, Kısa, Adnan , Kısa, Sezer , Kopec, Jacek A , Koteeswaran, Rajasekaran , Koul, Parvaiz A , Laxminarayana, Sindhura Lakshmi Koulmane , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, G Anil , Kurmi, Om , Kutluk, Tezer, Lami, Faris Hasan, Lee, Yo Han , Leigh, James , Leong, Elvynna , Li, Ming‐Chieh , Liu, Xuefeng , Loureiro, Joana A. , Lunevičius, Raimundas , Razek, Muhammed Magdy Abd El, Majeed, Azeem , Makki, Alaa, Male, Shilpa, Malik, Ahmad Azam , Martini, Santi , Masoumi, Seyedeh Zahra , Mehrotra, Ravi , Mendoza, Walter, Mengesha, Endalkachew Worku , Mesregah, Mohamed Kamal , Jonasson, Junmei Miao , Miazgowski, Bartosz , Miazgowski, Tomasz , Michałek, Irmina Maria , Miller, Ted R. , Mirzaei, Hamid Reza , Misra, Sanjeev , Mithra, Prasanna , Moghadaszadeh, Masoud, Mohammad, Karzan Abdulmuhsin , Mohammad, Yousef , Mohammadi, Mokhtar , Mohammadi, Seyyede Momeneh, Mohammadian-Hafshejani, Abdollah , Mohammed, Shafiu , Moka, Nagabhishek , Mokdad, Ali H. , Molokhia, Mariam , Monasta, Lorenzo , Moosavi, Mohammad Amin , Moradi, Yousef , Moraga, Paula , Morgado-da-Costa, Joana, Mubarik, Sumaira , Mwanri, Lillian , Nagarajan, Ahamarshan Jayaraman , Nagata, Chie , Naimzada, Mukhammad David , Nangia, Vinay, Naqvi, Atta Abbas , Swamy, Sreenivas Narasimha, Negoi, Ionuţ , Negru, Șerban , Kandel, Sandhya Neupane , Nguyen, Cuong Tat , Niazi, Robina Khan, Nnaji, Chukwudi A , Noor, Nurulamin M , Nzoputam, Chimezie Igwegbe , Oancea, Bogdan , Ogbo, Felix Akpojene , Olagunju, Andrew T , Olakunde, Babayemi O. , Omar, Emad, Bali, Ahmed Omar , Omonisi, Abidemi , Ong, Sokking, Onwujekwe, Obinna , Ortega-Altamirano, Doris V , Otstavnov, Stanislav S , Mahesh, P A , Pakshir, Keyvan , Pană, Adrian , Panagiotakos, Demosthenes B. , Panda‐Jonas, Songhomitra, Park, Eun‐Cheol , Park, Eun‐Kee , Kan, Fatemeh Pashazadeh , Patel, Harsh K. , Patel, Jenil , Pati, Siddhartha , Paudel, Uttam , Pereira, David M. , Pereira, Renato B. , Perianayagam, Arokiasamy , Pillay, Julian David , Pirouzpanah, Saeed , Podder, Indrashis , Postma, Maarten J. , Prashant, Akila , Preoțescu, Liliana , Rabiee, Navid , Radfar, Amir , Radhakrishnan, Raghu , Radhakrishnan, Venkatraman , Rahim, Fakher , Rahimzadeh, Shadi , Rahman, Mosiur , Rahman, Muhammad Aziz , Rajai, Nazanin , Rajesh, Aashish , Ram, Pradhum , Ramezanzadeh, Kiana, Ranabhat, Kamal , Rao, Chythra R , Rao, Sowmya J, Rawassizadeh, Reza , Razeghinia, Mohammad Sadegh , Rezapour, Aziz, Buendía, Jefferson Antonio , Rohloff, Peter , Rwegerera, Godfrey Mutashambara , Manjula, S, Saddik, Basema , Saeed, Umar , Sahoo, Harihar , Salehi, Sana , Salem, Marwa Rashad , Samaei, Mehrnoosh, Samy, Abdallah M , Sanabria, Juan , Sankararaman, Senthilkumar , Santric-Milicevic, Milena M , Sardiwalla, Yaeesh , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Šekerija, Mario , Seylani, Allen, Shafaat, Omid , Shaikh, Masood Ali , Shannawaz, Mohammed , Sheikhbahaei, Sara , Shetty, Adithi , Shetty, Jeevan K. , Shetty, Pavanchand H, Shirkoohi, Reza , Shivarov, Velizar , Malleshappa, Sudeep K Siddappa , Silva, Diego Augusto Santos , Sintayehu, Yitagesu , Skryabin, Valentin Yurievich , Soeberg, Matthew, Sofi‐Mahmudi, Ahmad , Steiropoulos, Paschalis , Straif, Kurt, Subedi, Ranjeeta , Sultana, Saima , Szerencsés, Viktória , Tabuchi, Takahiro , Tadbiri, Hooman , Takahashi, Ken , Tan, Ker‐Kan , Tat, Vivian Y, Tedla, Bemnet , Tefera, Yonas Getaye , Temsah, Mohamad‐Hani , Tesfay, Fisaha Haile , Tessema, Gizachew Assefa , Thavamani, Aravind , Chandrasekar, Viveksandeep Thoguluva , Touvier, Mathilde , Tovani‐Palone, Marcos Roberto , Traini, Eugenio , Tran, Mai Thi Ngoc , Tripathy, Jaya Prasad , Tusa, Biruk Shalmeno , Ullah, Irfan , Ullah, Saif , Umapathi, Krishna Kishore , Vaezi, Maryam, Tahbaz, Sahel Valadan , Velazquez, Diana Zuleika , Violante, Francesco Saverio , Volovici, Victor , Vu, Giang Thu , Waheed, Yasir , Ward, Paul , Wen, Yi Feng , Westerman, Ronny, Yadav, Lalit , Jabbari, Seyed Hossein Yahyazadeh, Yang, Lin , Yazie, Taklo Simeneh , Yeshaw, Yigizie , Younis, Mustafa Z , Yousefi, Zabihollah , Yunusa, Ismaeel , Zadnik, Vesna , Zare, Fariba , Застрожин, Михаил Сергеевич , Zastrozhina, Anasthasia, Zhang, Jianrong , Zhong, Chenwen, Zhu, Cong , Zimmermann, Ivan Ricardo , Fitzmaurice, Christina , Murray, Christopher J L , Force, Lisa M , Ong, Sok King , Eftekhari, Aziz , Guimarães, André Luiz Sena , Kumar, Vivek , Lami, Faris , Liu, Xuefeng , Baig, Atif Amin , Thoguluva Chandrasekar, Viveksandeep, Kumar, Vivek , Cao, Yin , Brenner, Hermann , Farzadfar, Farshad , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Guha, Avirup , Ebrahimi, Hedyeh , Volovici, Victor , Bhagavathula, Akshaya Srikanth , Jakovljević, Mihajlo , Elhadi, Muhammed , Abdoli, Amir , Adnani, Qorinah Estiningtyas Sakilah , Afzal, Muhammad Sohail, Ahinkorah, Bright Opoku , Ahmad, Sajjad , Ahmadi, Ali , Ahmadi, Sepideh , Akalu, Gizachew Taddesse , Al‐Aly, Ziyad , Ali, Saqib , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Anbesu, Etsay Woldu , Ancuceanu, Robert , Ansari‐Moghaddam, Alireza , Arab-Zozani, Morteza , Asemi, Zatollah , Aujayeb, Avinash , Azzam, Ahmed Y , Banach, Maciej , Barra, Fabio , Behzadifar, Masoud , Bezabhe, Woldesellassie M Mequanint , Bhardwaj, Pankaj , Bhattacharyya, Krittika , Biondi, Antonio , Bjørge, Tone , Bleyer, Archie , Blyuss, Oleg B. , Chaturvedi, Pankaj, Christopher, Devasahayam Jesudas , Chung, Michael T. , Cortesi, Paolo Angelo , Belachew, Amare , Dahlawi, Saad M A , Dai, Xiaochen , Darwesh, Aso Mohammad , Neves, José das , Demis, Asmamaw , Denova‐Gutiérrez, Edgar , Dhimal, Meghnath , Dianatinasab, Mostafa , Do, Huyen Phuc , Doaei, Saeid , Figueiredo, Francisco Winter dos Santos , El-Jaafary, Shaimaa I , Eskandarieh, Sharareh , Faraon, Emerito Jose A , Ferrero, Simone , Filip, Irina , Foroutan, Masoud , Gaál, Péter , Gadanya, Muktar A , Gallus, Silvano , Gomez, Ricardo Santiago , Grosso, Giuseppe , Gupta, Veer Bala , Haj‐Mirzaian, Arvin , Halwani, Rabih , Hamadeh, Randah R , Hamidi, Samer , Haro, Josep María , Hassanipour, Soheil , Hay, Roderick J. , Hayat, Khezar , Heidari, Mohammad , Holla, Ramesh , Hossain, Md Mahbub , Hostiuc, Sorin , Iavicoli, Ivo , Ilesanmi, Olayinka Stephen , Ilić, Milena , Islam, Rakibul M. , Jazayeri, Seyed Behzad , Kabir, Ali , Kahrizi, Danial , Kaliyadan, Feroze , Karch, André , Katikireddi, Srinivasa Vittal , Kauppila, Joonas H. , Kavetskyy, Taras , Kebede, Sewnet Adem , Khan, Gulfaraz , Khang, Young-Ho, Khayamzadeh, Maryam , Kim, Gyu Ri , Kim, Yun Jin , Kissimova‐Skarbek, Katarzyna , Koyanagi, Ai , Kumar, Narinder , Kumar, Nithin , Vecchia, Carlo La , Landires, Iván , Lauriola, Paolo , Lee, Sang Hyuck , Lee, Shaun Wen Huey , Lee, Wei‐Chen , Li, Jiarui , Mansournia, Mohammad Alì , Mathur, Prashant , McKee, Martin , Menezes, Ritesh G. , Meštrović, Tomislav , Mirzaei, Hamed , Moni, Mohammad Ali , Morrison, Shane D. , Mosapour, Abbas , Nagaraju, Shankar Prasad , Ndejjo, Rawlance , Nduaguba, Sabina O. , Nguyen, Huong Lan Thi , Núñez-Samudio, Virginia , Оchir, Chimedsuren , Odukoya, Oluwakemi Ololade , Ong, Sokking, Orru, Hans , Otstavnov, Nikita , Owolabi, Mayowa , Padubidri, Jagadish Rao , Pardhan, Shahina , Pattanshetty, Sanjay M. , Pishgar, Farhad , Pourjafar, Hadi , Rabiee, Mohammad , Rafiee, Ata , Rahmani, Amir Masoud , Rakovac, Ivo , Ranasinghe, Priyanga Diloshini , Renzaho, André M. N. , Rezaei, Negar , Rezaei, Nima , Roberts, Thomas J. , Romoli, Michele , Ronfani, Luca , Roshandel, Gholamreza , Sabour, Siamak , Sahebkar, Amirhossein , Salimzadeh, Hamideh , Şaylan, Mete , Schneider, Ione Jayce Ceola , Shaghaghi, Zahra , Shamsoddin, Erfan , Sharma, Rajesh , Sheikh, Aziz , Shibuya, Kenji , Shivakumar, K. M. , Siabani, Soraya , Singh, Jasvinder A. , Skryabina, Anna Aleksandrovna , Sotoudeh, Houman , Sufiyan, Mu’awiyyah Babale , Sultan, Iyad Yasin , Sur, Daniel Genel , Szócska, Miklós , Tabarés‐Seisdedos, Rafael , Taherkhani, Amir , Talaat, Iman Mamdouh , Tehrani‐Banihashemi, Arash , Thapar, Rekha , Thomas, Nihal , Tohidinik, Hamid Reza , Tran, Bach Xuan , Tran, Khanh Bao , Unnikrishnan, Bhaskaran , Upadhyay, Era , Vacante, Marco , Vaezi, Maryam, Veroux, Massimiliano , Vlassov, Vasily , Vo, Bay, Wamai, Richard G. , Winkler, Andrea Sylvia , Yaya, Sanni , Yonemoto, Naohiro , Yu, Chuanhua , Yüce, Deniz , Zhou, Linghui , Ziapour, Arash , Olagunju, Andrew T , Shivakumar, KM , Baig, Atif Amin , Alahdab, Fares , Asghari-Jafarabadi, Mohammad , Rahim, Fakher

Mayo Clinic

JAMA Oncology | December 30, 2021 | Volume: 8 | Issue: 3 | Pages: 420

10.1001/jamaoncol.2021.6987 | PMID 34967848 Get It

The Role of the Human Immune System in the Aging Process: a Mathematical Model of Cell and Cytokine Activation
Talaei, Kian, Garan, Steven A., Martins, Nuno, Cho, Joshua, Jahansooz, Julia, Bhullar, Puneet , Suen, Elliott K., Piszker, Walter, Cho, Hyong Jin

Mayo Clinic

Innovation in Aging | December 17, 2021 | Volume: 5 | Issue: Supplement_1 | Pages: 676-676

10.1093/geroni/igab046.2546 Get It

Abstract The role of the human immune system as a factor in the aging process has led to extensive research in the field of infection biology and bioinformatics. Cell-based mathematical models have previously been used to simulate the immune system in response to pathogens. A variety of cells, such as activated and resting macrophages, plasma cells, antibodies, helper T cells, T-lymphocytes, and B-lymphocytes, have already been simulated by mathematical models. This work aims to incorporate cytokines in these mathematical models to create a more comprehensive simulation that can predict cytokine levels in response to a Gram-positive bacterium, S. aureus. To accomplish this, the cytokines Tumor Necrosis Factor Alpha (TNF-α), Interleukin 6 (IL-6), Interleukin 8 (IL-8), and Interleukin 10 (IL-10) were studied to quantify the relationship between cytokine release from macrophages and the concentration of the pathogen, S. aureus ex vivo. The results of the simulation were compared to ex vivo human whole blood data to test its accuracy. The future expansion of this model may provide a clearer image of the various interactions within the immune system and this improved model of the immune system may also facilitate a better understanding of the mechanisms that lead to the degradation of the immune system during the aging process.
Transcriptomic analysis of Streptococcus agalactiae periprosthetic joint infection
Masters, Thao , Greenwood‐Quaintance, Kerryl E. , Johnson, Stephen , Pu, Meng , Patel, Robin , Cho, Hye-Kyung, Jeraldo, Patricio R , Patel, Robin , Cho, Hye-Kyung , Jeraldo, Patricio , Chia, Nicholas , Abdel, Matthew P.

Mayo Clinic

MicrobiologyOpen | December 17, 2021 | Volume: 10 | Issue: 6 | Pages: No page available

10.1002/mbo3.1256 | PMID 34964296 Get It

AbstractAlthough Streptococcus agalactiae periprosthetic joint infection (PJI) is not as prevalent as staphylococcal PJI, invasive S. agalactiae infection is not uncommon. Here, RNA‐seq was used to perform transcriptomic analysis of S. agalactiae PJI using fluid derived from sonication of explanted arthroplasties of subjects with S. agalactiae PJI, with results compared to those of S. agalactiae strain NEM316 grown in vitro. A total of 227 genes with outlier expression were found (164 upregulated and 63 downregulated) between PJI sonicate fluid and in vitro conditions. Functional enrichment analysis showed genes involved in mobilome and inorganic ion transport and metabolism to be most enriched. Genes involved in nickel, copper, and zinc transport, were upregulated. Among known virulence factors, cyl operon genes, encoding β‐hemolysin/cytolysin, were consistently highly expressed in PJI versus in vitro. The data presented provide insight into S. agalactiae PJI pathogenesis and may be a resource for identification of novel PJI therapeutics or vaccines against invasive S. agalactiae infections.
Anticachectic regulator analysis reveals Perp-dependent antitumorigenic properties of 3-methyladenine in pancreatic cancer
Arneson‐Wissink, Paige C. , Schmitt, R. , Cho, Dong Seong , Ducharme, Alexandra M. , Hogenson, Tara L. , Krueger, Eugene W. , Zhang, Lizhi , Fernández-Zapico, Martín E. , Schmitt, Rebecca E , Ducharme, Alexandra , Dasgupta, Aneesha , Bamlet, William R. , Razidlo, Gina L. , Doles, Jason D.

Mayo Clinic

JCI Insight | December 7, 2021 | Volume: 7 | Issue: 2 | Pages: No page available

10.1172/jci.insight.153842 | PMID 34874916 Get It

Approximately 80% of pancreatic cancer patients suffer from cachexia, and one-third die due to cachexia-related complications such as respiratory failure and cardiac arrest. Although there has been considerable research into cachexia mechanisms and interventions, there are, to date, no FDA-approved therapies. A major contributing factor for the lack of therapy options could be the failure of animal models to accurately recapitulate the human condition. In this study, we generated an aged model of pancreatic cancer cachexia to compare cachexia progression in young versus aged tumor-bearing mice. Comparative skeletal muscle transcriptome analyses identified 3-methyladenine (3-MA) as a candidate antiwasting compound. In vitro analyses confirmed antiwasting capacity, while in vivo analysis revealed potent antitumor effects. Transcriptome analyses of 3-MA–treated tumor cells implicated Perp as a 3-MA target gene. We subsequently (a) observed significantly higher expression of Perp in cancer cell lines compared with control cells, (b) noted a survival disadvantage associated with elevated Perp , and (c) found that 3-MA–associated Perp reduction inhibited tumor cell growth. Finally, we have provided in vivo evidence that survival benefits conferred by 3-MA administration are independent of its effect on tumor progression. Taken together, we report a mechanism linking 3-MA to Perp inhibition, and we further implicate Perp as a tumor-promoting factor in pancreatic cancer.
Tonic Serotonin Measurements In Vivo Using N-Shaped Multiple Cyclic Square Wave Voltammetry
Shin, Hojin , Goyal, Abhinav , Barnett, J. Hudson , Rusheen, Aaron E. , Jha, Rohan , Hwang, Sang Mun, Kang, Yumin , Park, Cheonho , Cho, Hyun‐U , Bennet, Kevin E. , Heien, Michael L. , Jang, Dong Pyo , Lee, Kendall H. , Yuen, Jason , Kang, Yumin , Oh, Yoonbae , Heien, Michael L , Jang, Dong Pyo , Jha, Rohan, Blaha, Charles D. , Oh, Yoonbae

Mayo Clinic

Analytical Chemistry | December 2, 2021 | Volume: 93 | Issue: 51 | Pages: 16987-16994

10.1021/acs.analchem.1c02131 | PMID 34855368 Get It

Enhanced Dopamine Sensitivity Using Steered Fast-Scan Cyclic Voltammetry
Kang, Yumin , Goyal, Abhinav , Hwang, Sangmun, Park, Cheonho , Cho, Hyun U., Shin, Hojin , Park, Jinsick , Bennet, Kevin E. , Lee, Kendall H. , Oh, Yoonbae , Jang, Dong Pyo , Oh, Yoonbae

Mayo Clinic

ACS Omega | December 1, 2021 | Volume: 6 | Issue: 49 | Pages: 33599-33606

10.1021/acsomega.1c04475 | PMID 34926907 Get It

Feasibility of Applying Fourier Transform Electrochemical Impedance Spectroscopy in Fast Cyclic Square Wave Voltammetry for theIn VivoMeasurement of Neurotransmitters
Park, Cheonho , Hwang, Sangmun, Kang, Yumin , Sim, Jeongeun, Cho, Hyun U., Oh, Yoonbae , Shin, Hojin , Bennet, Kevin E. , Lee, Kendall H. , Jang, Dong Pyo , Jang, Dong Pyo , Oh, Yoonbae , Kim, Do Hyoung, Blaha, Charles D.

Mayo Clinic

Analytical Chemistry | November 29, 2021 | Volume: 93 | Issue: 48 | Pages: 15861-15869

10.1021/acs.analchem.1c02308 | PMID 34839667 Get It

Transcriptomic analysis of Streptococcus agalactiae periprosthetic joint infection
Masters, Thao , Greenwood‐Quaintance, Kerryl E. , Johnson, Stephen , Pu, Meng , Cho, Hye-Kyung , Jeraldo, Patricio , Chia, Nicholas , Abdel, Matthew P. , Patel, Robin

Mayo Clinic

No container title available | November 27, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.163803783.32306564/v1 Get It

Although Streptococcus agalactiae periprosthetic joint infection (PJI) is not as prevalent as staphylococcal PJI, invasive S. agalactiae infection has recently increased in incidence. Here, RNA-Seq was used to perform transcriptomic analysis of S. agalactiae PJI using fluid derived from sonication of explanted arthroplasties of subjects with S. agalactiae PJI, with results compared to those of S. agalactiae strain NEM316 grown in vitro. 227 genes with outlier expression were found (164 up-regulated and 63 down-regulated) between PJI sonicate fluid and in vitro conditions. Functional enrichment analysis showed genes involved in mobilome and inorganic ion transport and metabolism to be most enriched. Genes involved in nickel, copper, and zinc transport, were upregulated. Among known virulence factors, cyl operon genes, encoding beta-hemolysin/cytolysin, were consistently highly expressed in PJI versus in vitro. The data presented provide insight into S. agalactiae PJI pathogenesis and may be a useful resource for the identification of novel PJI therapeutics or vaccines against invasive S. agalactiae infections.
Characterization of T-Cell Exhaustion in Rapid Progressing Multiple Myeloma Using Cross Center Scrna-Seq Study
Thomas, Beena , Kourelis, Taxiarchis , Dhodapkar, Madhav V. , Vij, Ravi , Kumar, Shaji , Mehr, Shaadi , Hamilton, Mark , Auclair, Daniel , Avigan, David , Gnjatic, Sacha , Ding, Li , Gnjatic, Sacha , Pilcher, William , Thomas, Beena E, Bhasin, Swati S. , Jayasinghe, Reyka G. , Rahman, Adeeb H , Kim-Schulze, Seunghee , Gonzalez‐Kozlova, Edgar , Cho, Hearn Jay , Bhasin, Manoj K

Mayo Clinic

Blood | November 24, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 401-401

10.1182/blood-2021-153863 Get It

Abstract Introduction: Multiple myeloma (MM) is a complex hematological malignancy with the heterogenous immune bone marrow (BM) environment contributing to tumor growth, drug resistance, and immune escape. T-Cells play a critical role in the clearance of malignant plasma cells from the tumor environment. However, T-Cells in multiple myeloma demonstrate impaired cytotoxicity, proliferation, and cytokine production due to the activation of immune inhibitory receptors from ligands produced by the myeloma cells. In this study, we investigate the behavior of T-Cells in MM patients by using single-cell RNA-Seq (scRNA-Seq) to compare the transcriptomic profiles of BM T-Cells of patients with rapid progressing (FP; PFS < 18mo) and non-progressing (NP; PFS > 4yrs) disease. Methods: Newly diagnosed MM patients (n=18) from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study (NCT01454297) were identified as either rapid progressors or non-progressors based on their progression free survival since diagnosis. To capture transcriptomic data, scRNA-Seq was performed on 48 aliquots of frozen CD138-negative BM cells at three medical centers/universities (Beth Israel Deaconess Medical Center, Boston, Washington University in St. Louis, and Mount Sinai School of Medicine, NYC). Samples were collected at diagnosis prior to treatment. Surface marker expression for 29 proteins was captured for at least one sample per patient using CITE-Seq. After integration and batch correction, clustering was performed to identify cells of T or NK lineage. Uniform Manifold Approximation and Projection (UMAP) and differential expression were used to identify T-Lymphoid subtypes, and differences in NP and FP samples. Results: In this study, single cell transcriptomic profiles were identified for ~102,207 cells from 48 samples of 18 MM patients. 40,328 T (CD3+) and NK (CD3-, NKG7+) cells were isolated, and subclustered for further analysis (Fig 1A). Using differentially expressed markers for each cluster, the T-Lymphoid subset was refined into seven subtypes, consisting of various CD4+ T-Cells, CD8+ T-Cells, and NK cells (Fig 1B). The CD8+ cells were divided into three distinct phenotypes, namely a GZMK-, GZMB- CD8+ T-Cell cluster, a GZMK+ CD8+ Exhausted T-Cell cluster enriched in TIGIT and multiple chemokines (CCL3, CCL4, XCL2), and a GZMB+ NkT cluster enriched in cytolytic markers (PRF1, GNLY, NKG7) (Fig 1C). Differential expression between NP and FP samples in this CD8+ subset showed enrichment of the NkT cytotoxic markers in NP samples, while FP samples were enriched in the CD8+ Exhausted chemokine markers (Fig 1D). Furthermore, the proportion of CD8+ Exhausted T-Cells was enriched in FP samples (p.val < 0.05) (Fig 1E). Exhaustion markers were measured through both RNA and surface marker levels. In RNA, TIGIT was uniquely associated with the FP-enriched CD8+ Exhausted T-Cell cluster, and CD160 was uniquely expressed in FP samples (Fig 1F). CITE-Seq surface marker expression confirms enrichment of both TIGIT and PD1 in the CD8+ Exhausted T-Cell cluster, and along with more exhaustion in FP samples (p.val < 0.01). Conclusion: In this study, we have identified significant differences in T-Cell activity in patients with non-progressing and rapid-progressing multiple myeloma. T-Cells in rapid progressing patients appear to be in a suppressed state, with low cytolytic activity and enriched exhaustion markers. This GZMK+ T-Cell population shows strong similarities with an aging-associated subtype of effector memory T-Cells found to be enriched in older populations (Mogilenko et al, Immunity 54, 2021). These findings will be further validated in an expanded study, consisting both of a larger number of samples, and multiple samples at different timepoints from the same patient. Figure 1 Figure 1. Disclosures Jayasinghe: MMRF: Consultancy; WUGEN: Consultancy. Vij: BMS: Research Funding; Takeda: Honoraria, Research Funding; Sanofi: Honoraria, Research Funding; BMS: Honoraria; GSK: Honoraria; Oncopeptides: Honoraria; Karyopharm: Honoraria; CareDx: Honoraria; Legend: Honoraria; Biegene: Honoraria; Adaptive: Honoraria; Harpoon: Honoraria. Kumar: Carsgen: Research Funding; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Beigene: Consultancy; Bluebird Bio: Consultancy; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Tenebio: Research Funding; Oncopeptides: Consultancy; Antengene: Consultancy, Honoraria; Roche-Genentech: Consultancy, Research Funding; Merck: Research Funding; Astra-Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Research Funding; Amgen: Consultancy, Research Funding; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Consultancy, Research Funding; Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Research Funding. Avigan: Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Research Funding; Kite Pharma: Consultancy, Research Funding; Juno: Membership on an entity's Board of Directors or advisory committees; Partner Tx: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Aviv MedTech Ltd: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Legend Biotech: Membership on an entity's Board of Directors or advisory committees; Chugai: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy; Parexcel: Consultancy; Takeda: Consultancy; Sanofi: Consultancy.
Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study
Wang, Tianjiao , Sato, Kazuhiro , Kourelis, Taxiarchis , Thomas, Beena , Lee, Brian , Upadhyaya, Bhaskar , Fortier, Julie M. , Dawson, Travis , Kumar, Shaji , Raj, Bee, Vij, Ravi , Vlachos, Ioannis S. , Mehr, Shaadi , Hamilton, Mark , Auclair, Daniel , Dasari, Surendra , Avigan, David , Dhodapkar, Madhav V. , Gnjatic, Sacha , Ding, Li , Gnjatic, Sacha , Vlachos, Ioannis S , Yao, Lijun , Jayasinghe, Reyka G. , Pilcher, William , Gonzalez‐Kozlova, Edgar , Pita-Juárez, Yered , Doxie, Deon Bryant , Thomas, Beena E, Bhasin, Swati S. , Fiala, Mark A. , Leech, John M. , Cho, Hearn Jay , Kim-Schulze, Seunghee , Oh, Stephen T. , DiPersio, John F. , Rahman, Adeeb H , Bhasin, Manoj K

Mayo Clinic

Blood | November 24, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 2691-2691

10.1182/blood-2021-154081 Get It

Abstract Multiple Myeloma (MM) is the second most common hematologic malignancy, marked by uncontrolled clonal expansion of plasma cells. MM genome is complex and heterogeneous, with a high frequency of structural variants (SVs) and copy-number abnormalities (CNAs). Single-cell sequencing technologies offer advantages over traditional bulk methods in cancer genomics research for evaluating cellular heterogeneity and investigating evolution of cellular subpopulations within the tumor. Thus, there is an impetus to translate the growing understanding of the genomic landscape of MM into dissecting the tumor heterogeneity using scRNA-seq. So far, there are no reported studies systematically comparing tumor and immune populations differences between MM NON-progressors (NPs) and RAPID-progressor (RPs) and investigating how clonal plasma cells contribute to progression in a large cohort. In addition, the bone marrow microenvironment plays an important role in the evolution of premalignant MM and MM progression. A previous study of single-cell transcriptomics analysis of Monoclonal gammopathy of undetermined significance (MGUS) and MM tumor microenvironment (TME) revealed that natural killer (NK) cell abundance is frequently increased in the early stages and associated with altered chemokine receptor expression. This study shed the light on the role of immune cells on disease progression from asymptomatic MGUS to symptomatic MM. However to date, how immune cells influence disease progression within symptomatic MM is still unclear. Here, we subjected 344 CD138-negative Bone Marrow Mononuclear cells (BMMC) samples to scRNA-seq. To control for the first line therapy, 272 patients were treated with RVD and Autologous stem cell transplant (ASCT) and were stratified into 3 groups based on progression: 200 NON-progressors (NPs) (PFS> 5 years), 7 Intermediate Progressors (IPs, PFS 2-4 years) and 38 RAPID-progressors (RPs) (PFS<=18 months). In addition, there are 72 subjects treated with RVD but without ASCT, including 34 NPs, 2 IPs and 36 RPs. From MMRF CoMMpass study (NCT01454297), we also have whole exome sequencing (WES) and bulk RNA-seq from CD138-positive fraction of BMMC samples. Our preliminary analysis of scRNA-seq of 6 samples treated by the same first-line therapies (RVD but without ASCT) revealed that plasma cells (PCs) from two patients (MMRF2550 and MMRF2562) with chromosome 13q deletion clustered together, whereas PCs from a patient (MMRF2187) with t(8;14) Myc translocation formed a distinct cluster. Interestingly, PCs from a patient (MMRF2271) with both chromosome 13q deletion and t(8;14) formed another independent cluster. These observations highlight the important role of genetic drivers in transcriptome profiles of plasma cells. In addition, we further investigated how progression features correlate with the immune microenvironment and identified differentially expressed genes between NK cells from RPs versus those from NPs, which could potentially serve as MM progression markers. Interestingly, several cytotoxicity genes are significantly upregulated in FPs, such as GZMB and KLRB1 (log Fold Change=1.44, and 8.41 respectively). Overall, our preliminary results provide a small glimpse of the interconnected nature of driver genetic alterations and progression features in MM tumor and TME. This study will provide a sufficiently broad, deep, and diverse vast dataset for accurately characterizing MM at single-cell resolution to help interrogate how genetic alterations and disease progression interplay MM tumor and TME. We hope this study could identify novel candidate targets for therapeutic approaches, and ultimately stratify patients by risk of progression for early intervention in the clinic. Disclosures Kumar: Roche-Genentech: Consultancy, Research Funding; Merck: Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Research Funding; Novartis: Research Funding; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Beigene: Consultancy; Carsgen: Research Funding; Bluebird Bio: Consultancy; Astra-Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Oncopeptides: Consultancy; Tenebio: Research Funding; BMS: Consultancy, Research Funding; Antengene: Consultancy, Honoraria; Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Research Funding. Oh: Abbvie: Membership on an entity's Board of Directors or advisory committees; Blueprint Medicines: Membership on an entity's Board of Directors or advisory committees; Celgene Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Constellation: Membership on an entity's Board of Directors or advisory committees; CTI Biopharma: Membership on an entity's Board of Directors or advisory committees; Disc Medicine: Membership on an entity's Board of Directors or advisory committees; Geron: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Kartos Therapeutics: Membership on an entity's Board of Directors or advisory committees; PharamaEssentia: Membership on an entity's Board of Directors or advisory committees; Sierra Oncology: Membership on an entity's Board of Directors or advisory committees. Vij: BMS: Research Funding; Takeda: Honoraria, Research Funding; Sanofi: Honoraria, Research Funding; BMS: Honoraria; GSK: Honoraria; Oncopeptides: Honoraria; Karyopharm: Honoraria; CareDx: Honoraria; Legend: Honoraria; Biegene: Honoraria; Adaptive: Honoraria; Harpoon: Honoraria. Avigan: Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Research Funding; Kite Pharma: Consultancy, Research Funding; Juno: Membership on an entity's Board of Directors or advisory committees; Partner Tx: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Aviv MedTech Ltd: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Legend Biotech: Membership on an entity's Board of Directors or advisory committees; Chugai: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy; Parexcel: Consultancy; Takeda: Consultancy; Sanofi: Consultancy.